Exact Mass: 716.4334

Exact Mass Matches: 716.4334

Found 241 metabolites which its exact mass value is equals to given mass value 716.4334, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

PA(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))

[(2R)-2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyloxy]-3-[(6Z,9Z,12Z)-octadeca-6,9,12-trienoyloxy]propoxy]phosphonic acid

C41H65O8P (716.4417)


PA(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z)), in particular, consists of one chain of gamma-linolenic acid at the C-1 position and one chain of eicosapentaenoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

PA(18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))

[(2R)-2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyloxy]-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyloxy]propoxy]phosphonic acid

C41H65O8P (716.4417)


PA(18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z)), in particular, consists of one chain of alpha-linolenic acid at the C-1 position and one chain of eicosapentaenoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

PA(18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))

[(2R)-2-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyloxy]-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyloxy]propoxy]phosphonic acid

C41H65O8P (716.4417)


PA(18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)), in particular, consists of one chain of stearidonic acid at the C-1 position and one chain of arachidonic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

PA(18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z))

[(2R)-2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyloxy]-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyloxy]propoxy]phosphonic acid

C41H65O8P (716.4417)


PA(18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:4(6Z,9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)), in particular, consists of one chain of stearidonic acid at the C-1 position and one chain of eicosatetraenoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

PA(20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))

[(2R)-3-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyloxy]-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyloxy]propoxy]phosphonic acid

C41H65O8P (716.4417)


PA(20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z)), in particular, consists of one chain of arachidonic acid at the C-1 position and one chain of stearidonic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

PA(20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z))

[(2R)-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyloxy]-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyloxy]propoxy]phosphonic acid

C41H65O8P (716.4417)


PA(20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:4(8Z,11Z,14Z,17Z)/18:4(6Z,9Z,12Z,15Z)), in particular, consists of one chain of eicosatetraenoic acid at the C-1 position and one chain of stearidonic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

PA(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))

[(2R)-3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyloxy]-2-[(6Z,9Z,12Z)-octadeca-6,9,12-trienoyloxy]propoxy]phosphonic acid

C41H65O8P (716.4417)


PA(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z)), in particular, consists of one chain of eicosapentaenoic acid at the C-1 position and one chain of gamma-linolenic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

PA(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))

[(2R)-3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyloxy]-2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyloxy]propoxy]phosphonic acid

C41H65O8P (716.4417)


PA(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z)), in particular, consists of one chain of eicosapentaenoic acid at the C-1 position and one chain of alpha-linolenic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

   

PA(14:0/PGE2)

[(2R)-2-{[(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoyl]oxy}-3-(tetradecanoyloxy)propoxy]phosphonic acid

C37H65O11P (716.4264)


PA(14:0/PGE2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:0/PGE2), in particular, consists of one chain of one tetradecanoyl at the C-1 position and one chain of Prostaglandin E2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGE2/14:0)

[(2R)-3-{[(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoyl]oxy}-2-(tetradecanoyloxy)propoxy]phosphonic acid

C37H65O11P (716.4264)


PA(PGE2/14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGE2/14:0), in particular, consists of one chain of one Prostaglandin E2 at the C-1 position and one chain of tetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:0/PGD2)

[(2R)-2-{[(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoyl]oxy}-3-(tetradecanoyloxy)propoxy]phosphonic acid

C37H65O11P (716.4264)


PA(14:0/PGD2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:0/PGD2), in particular, consists of one chain of one tetradecanoyl at the C-1 position and one chain of Prostaglandin D2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGD2/14:0)

[(2R)-3-{[(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoyl]oxy}-2-(tetradecanoyloxy)propoxy]phosphonic acid

C37H65O11P (716.4264)


PA(PGD2/14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGD2/14:0), in particular, consists of one chain of one Prostaglandin D2 at the C-1 position and one chain of tetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

[(2R)-3-(tetradecanoyloxy)-2-{[(5S,6S,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C37H65O11P (716.4264)


PA(14:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)), in particular, consists of one chain of one tetradecanoyl at the C-1 position and one chain of Lipoxin A4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/14:0)

[(2R)-2-(tetradecanoyloxy)-3-{[(5R,6R,7E,9E,11Z,13E,15R)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C37H65O11P (716.4264)


PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/14:0), in particular, consists of one chain of one Lipoxin A4 at the C-1 position and one chain of tetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/PGF2alpha)

[(2R)-2-{[(5E)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]hept-5-enoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H65O11P (716.4264)


PA(14:1(9Z)/PGF2alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/PGF2alpha), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of Prostaglandin F2alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGF2alpha/14:1(9Z))

[(2R)-3-{[(5E)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]hept-5-enoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H65O11P (716.4264)


PA(PGF2alpha/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGF2alpha/14:1(9Z)), in particular, consists of one chain of one Prostaglandin F2alpha at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/PGE1)

[(2R)-2-({7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]heptanoyl}oxy)-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H65O11P (716.4264)


PA(14:1(9Z)/PGE1) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/PGE1), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of Prostaglandin E1 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGE1/14:1(9Z))

[(2R)-3-({7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]heptanoyl}oxy)-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H65O11P (716.4264)


PA(PGE1/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGE1/14:1(9Z)), in particular, consists of one chain of one Prostaglandin E1 at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/PGD1)

[(2R)-2-({7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]heptanoyl}oxy)-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H65O11P (716.4264)


PA(14:1(9Z)/PGD1) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/PGD1), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of Prostaglandin D1 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGD1/14:1(9Z))

[(2R)-3-({7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]heptanoyl}oxy)-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C37H65O11P (716.4264)


PA(PGD1/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGD1/14:1(9Z)), in particular, consists of one chain of one Prostaglandin D1 at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(15:0/20:3(8Z,11Z,14Z)-2OH(5,6))

[(2R)-2-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}-3-(pentadecanoyloxy)propoxy]phosphonic acid

C38H69O10P (716.4628)


PA(15:0/20:3(8Z,11Z,14Z)-2OH(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(15:0/20:3(8Z,11Z,14Z)-2OH(5,6)), in particular, consists of one chain of one pentadecanoyl at the C-1 position and one chain of 5,6-dihydroxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/15:0)

[(2R)-3-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}-2-(pentadecanoyloxy)propoxy]phosphonic acid

C38H69O10P (716.4628)


PA(20:3(8Z,11Z,14Z)-2OH(5,6)/15:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-2OH(5,6)/15:0), in particular, consists of one chain of one 5,6-dihydroxyeicosatrienoyl at the C-1 position and one chain of pentadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(16:1(9Z)/5-iso PGF2VI)

[(2R)-2-{[(3Z)-5-[(1S,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]cyclopentyl]pent-3-enoyl]oxy}-3-[(9Z)-hexadec-9-enoyloxy]propoxy]phosphonic acid

C37H65O11P (716.4264)


PA(16:1(9Z)/5-iso PGF2VI) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(16:1(9Z)/5-iso PGF2VI), in particular, consists of one chain of one 9Z-hexadecenoyl at the C-1 position and one chain of 5-iso Prostaglandin F2alpha-VI at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(16:1(9Z)/20:4(6E,8Z,11Z,14Z)+=O(5))

[(2R)-3-{[(3Z)-5-[(1S,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3R)-3-hydroxyoct-1-en-1-yl]cyclopentyl]pent-3-enoyl]oxy}-2-[(9Z)-hexadec-9-enoyloxy]propoxy]phosphonic acid

C37H65O11P (716.4264)


PA(16:1(9Z)/20:4(6E,8Z,11Z,14Z)+=O(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(16:1(9Z)/20:4(6E,8Z,11Z,14Z)+=O(5)), in particular, consists of one chain of one 9Z-hexadecenoyl at the C-1 position and one chain of 5-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(a-15:0/20:3(8Z,11Z,14Z)-2OH(5,6))

[(2R)-2-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}-3-[(12-methyltetradecanoyl)oxy]propoxy]phosphonic acid

C38H69O10P (716.4628)


PA(a-15:0/20:3(8Z,11Z,14Z)-2OH(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-15:0/20:3(8Z,11Z,14Z)-2OH(5,6)), in particular, consists of one chain of one 12-methyltetradecanoyl at the C-1 position and one chain of 5,6-dihydroxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/a-15:0)

[(2R)-3-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}-2-[(12-methyltetradecanoyl)oxy]propoxy]phosphonic acid

C38H69O10P (716.4628)


PA(20:3(8Z,11Z,14Z)-2OH(5,6)/a-15:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-2OH(5,6)/a-15:0), in particular, consists of one chain of one 5,6-dihydroxyeicosatrienoyl at the C-1 position and one chain of 12-methyltetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-14:0/PGE2)

[(2R)-2-{[(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoyl]oxy}-3-[(12-methyltridecanoyl)oxy]propoxy]phosphonic acid

C37H65O11P (716.4264)


PA(i-14:0/PGE2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-14:0/PGE2), in particular, consists of one chain of one 12-methyltridecanoyl at the C-1 position and one chain of Prostaglandin E2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGE2/i-14:0)

[(2R)-3-{[(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoyl]oxy}-2-[(12-methyltridecanoyl)oxy]propoxy]phosphonic acid

C37H65O11P (716.4264)


PA(PGE2/i-14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGE2/i-14:0), in particular, consists of one chain of one Prostaglandin E2 at the C-1 position and one chain of 12-methyltridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-14:0/PGD2)

[(2R)-2-{[(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoyl]oxy}-3-[(12-methyltridecanoyl)oxy]propoxy]phosphonic acid

C37H65O11P (716.4264)


PA(i-14:0/PGD2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-14:0/PGD2), in particular, consists of one chain of one 12-methyltridecanoyl at the C-1 position and one chain of Prostaglandin D2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(PGD2/i-14:0)

[(2R)-3-{[(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]hept-5-enoyl]oxy}-2-[(12-methyltridecanoyl)oxy]propoxy]phosphonic acid

C37H65O11P (716.4264)


PA(PGD2/i-14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGD2/i-14:0), in particular, consists of one chain of one Prostaglandin D2 at the C-1 position and one chain of 12-methyltridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-14:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

[(2R)-3-[(12-methyltridecanoyl)oxy]-2-{[(5S,6S,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C37H65O11P (716.4264)


PA(i-14:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-14:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)), in particular, consists of one chain of one 12-methyltridecanoyl at the C-1 position and one chain of Lipoxin A4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/i-14:0)

[(2R)-2-[(12-methyltridecanoyl)oxy]-3-{[(5R,6R,7E,9E,11Z,13E,15R)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C37H65O11P (716.4264)


PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/i-14:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/i-14:0), in particular, consists of one chain of one Lipoxin A4 at the C-1 position and one chain of 12-methyltridecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-15:0/20:3(8Z,11Z,14Z)-2OH(5,6))

[(2R)-2-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}-3-[(13-methyltetradecanoyl)oxy]propoxy]phosphonic acid

C38H69O10P (716.4628)


PA(i-15:0/20:3(8Z,11Z,14Z)-2OH(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-15:0/20:3(8Z,11Z,14Z)-2OH(5,6)), in particular, consists of one chain of one 13-methyltetradecanoyl at the C-1 position and one chain of 5,6-dihydroxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/i-15:0)

[(2R)-3-{[(8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoyl]oxy}-2-[(13-methyltetradecanoyl)oxy]propoxy]phosphonic acid

C38H69O10P (716.4628)


PA(20:3(8Z,11Z,14Z)-2OH(5,6)/i-15:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-2OH(5,6)/i-15:0), in particular, consists of one chain of one 5,6-dihydroxyeicosatrienoyl at the C-1 position and one chain of 13-methyltetradecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

Mediasteroside M2

Mediasteroside M2

C37H64O13 (716.4347)


   

Kulomoopunalide-1

Kulomoopunalide-1

C39H64N4O8 (716.4724)


   
   

3-(E)-Coumaroylbetulin-28-yl ethyl succinate

(+)-3-(E)-Coumaroylbetulin-28-yl ethyl succinate

C45H64O7 (716.4652)


   
   

Argentinic acid E

Argentinic acid E

C41H64O10 (716.4499)


   

21,23-epoxy-3alpha,7alpha,21,24,25-pentaacetoxy-4alpha,4beta,8beta-trimethyl-14,18-cyclo-5alpha,13alpha,14alpha,17alpha-cholestane

21,23-epoxy-3alpha,7alpha,21,24,25-pentaacetoxy-4alpha,4beta,8beta-trimethyl-14,18-cyclo-5alpha,13alpha,14alpha,17alpha-cholestane

C40H60O11 (716.4135)


   

2-deoxycucurbitacin F 16-O-(2?,3?-di-O-acetyl-4?-deoxy-alpha-allopyranoside)|datiscoside N

2-deoxycucurbitacin F 16-O-(2?,3?-di-O-acetyl-4?-deoxy-alpha-allopyranoside)|datiscoside N

C40H60O11 (716.4135)


   

Phe Tyr Phe Lys Ile

Phe Tyr Phe Lys Ile

C39H52N6O7 (716.3897)


   

Pleiokomenine A

Pleiokomenine A

C45H56N4O4 (716.4301)


   

FYFKI

Phe-Tyr-Phe-Lys-Ile

C39H52N6O7 (716.3897)


   

PG(12:0/20:3(8Z,11Z,14Z))

1-dodecanoyl-2-(8Z,11Z,14Z-eicosatrienoyl)-glycero-3-phospho-(1-sn-glycerol)

C38H69O10P (716.4628)


   

PG(14:0/18:3(6Z,9Z,12Z))

1-tetradecanoyl-2-(6Z,9Z,12Z-octadecatrienoyl)-glycero-3-phospho-(1-sn-glycerol)

C38H69O10P (716.4628)


   

PG(14:1(9Z)/18:2(9Z,12Z))

1-(9Z-tetradecenoyl)-2-(9Z,12Z-octadecadienoyl)-glycero-3-phospho-(1-sn-glycerol)

C38H69O10P (716.4628)


   

PG(15:1(9Z)/17:2(9Z,12Z))

1-(9Z-pentadecenoyl)-2-(9Z,12Z-heptadecadienoyl)-glycero-3-phospho-(1-sn-glycerol)

C38H69O10P (716.4628)


   

PG(17:2(9Z,12Z)/15:1(9Z))

1-(9Z,12Z-heptadecadienoyl)-2-(9Z-pentadecenoyl)-glycero-3-phospho-(1-sn-glycerol)

C38H69O10P (716.4628)


   

PG(18:2(9Z,12Z)/14:1(9Z))

1-(9Z,12Z-octadecadienoyl)-2-(9Z-tetradecenoyl)-glycero-3-phospho-(1-sn-glycerol)

C38H69O10P (716.4628)


   

PG(18:3(6Z,9Z,12Z)/14:0)

1-(6Z,9Z,12Z-octadecatrienoyl)-2-tetradecanoyl-glycero-3-phospho-(1-sn-glycerol)

C38H69O10P (716.4628)


   

PG(18:3(9Z,12Z,15Z)/14:0)

1-(9Z,12Z,15Z-octadecatrienoyl)-2-tetradecanoyl-glycero-3-phospho-(1-sn-glycerol)

C38H69O10P (716.4628)


   

PG(20:3(8Z,11Z,14Z)/12:0)

1-(8Z,11Z,14Z-eicosatrienoyl)-2-dodecanoyl-glycero-3-phospho-(1-sn-glycerol)

C38H69O10P (716.4628)


   

PG(14:0/18:3(9Z,12Z,15Z))

1-tetradecanoyl-2-(9Z,12Z,15Z-octadecatrienoyl)-glycero-3-phospho-(1-sn-glycerol)

C38H69O10P (716.4628)


   

PA(18:3(6Z,9Z,12Z)/20:5(5Z,8Z,11Z,14Z,17Z))

1-(6Z,9Z,12Z-octadecatrienoyl)-2-(5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl)-glycero-3-phosphate

C41H65O8P (716.4417)


   

PA(18:3(9Z,12Z,15Z)/20:5(5Z,8Z,11Z,14Z,17Z))

1-(9Z,12Z,15Z-octadecatrienoyl)-2-(5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl)-glycero-3-phosphate

C41H65O8P (716.4417)


   

PA(18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))

1-(6Z,9Z,12Z,15Z-octadecatetraenoyl)-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-glycero-3-phosphate

C41H65O8P (716.4417)


   

PA(20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))

1-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-2-(6Z,9Z,12Z,15Z-octadecatetraenoyl)-glycero-3-phosphate

C41H65O8P (716.4417)


   

PA(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(6Z,9Z,12Z))

1-(5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl)-2-(6Z,9Z,12Z-octadecatrienoyl)-glycero-3-phosphate

C41H65O8P (716.4417)


   

PA(20:5(5Z,8Z,11Z,14Z,17Z)/18:3(9Z,12Z,15Z))

1-(5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl)-2-(9Z,12Z,15Z-octadecatrienoyl)-glycero-3-phosphate

C41H65O8P (716.4417)


   

Evasterioside E

(20R,24S)-3,24-di-O-(beta-D-xylopyranosyl)-cholest-4-ene-3beta,6beta,8,15alpha,24-pentaol

C37H64O13 (716.4347)


   

PG 32:3

1-(9Z,12Z-heptadecadienoyl)-2-(9Z-pentadecenoyl)-glycero-3-phospho-(1-sn-glycerol)

C38H69O10P (716.4628)


   

PA 38:8

1-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-2-(6Z,9Z,12Z,15Z-octadecatetraenoyl)-glycero-3-phosphate

C41H65O8P (716.4417)


   

Bis(2,4,6-tri-ter-butyllphenyl)pentaerythritol-di-phosphite

Bis(2,4,6-tri-ter-butyllphenyl)pentaerythritol-di-phosphite

C41H66O6P2 (716.4334)


   

methyl 2-((2R,4aS,6S,7R,8S,8aS)-7,8- bis((tert-butyldimethylsilyl)oxy)-6-((S,E)-1- ((tert-butyldimethylsilyl)oxy)-3- (trimethylsilyl)allyl)octahydropyrano [3,2- b]pyran-2-yl)acetate

methyl 2-((2R,4aS,6S,7R,8S,8aS)-7,8- bis((tert-butyldimethylsilyl)oxy)-6-((S,E)-1- ((tert-butyldimethylsilyl)oxy)-3- (trimethylsilyl)allyl)octahydropyrano [3,2- b]pyran-2-yl)acetate

C35H72O7Si4 (716.4355)


   

PA(i-14:0/PGE2)

PA(i-14:0/PGE2)

C37H65O11P (716.4264)


   

PA(PGE2/i-14:0)

PA(PGE2/i-14:0)

C37H65O11P (716.4264)


   

PA(i-14:0/PGD2)

PA(i-14:0/PGD2)

C37H65O11P (716.4264)


   

PA(PGD2/i-14:0)

PA(PGD2/i-14:0)

C37H65O11P (716.4264)


   

PA(14:1(9Z)/PGF2alpha)

PA(14:1(9Z)/PGF2alpha)

C37H65O11P (716.4264)


   

PA(PGF2alpha/14:1(9Z))

PA(PGF2alpha/14:1(9Z))

C37H65O11P (716.4264)


   
   
   
   
   

PA(14:1(9Z)/PGE1)

PA(14:1(9Z)/PGE1)

C37H65O11P (716.4264)


   

PA(PGE1/14:1(9Z))

PA(PGE1/14:1(9Z))

C37H65O11P (716.4264)


   

PA(14:1(9Z)/PGD1)

PA(14:1(9Z)/PGD1)

C37H65O11P (716.4264)


   

PA(PGD1/14:1(9Z))

PA(PGD1/14:1(9Z))

C37H65O11P (716.4264)


   

PA(16:1(9Z)/5-iso PGF2VI)

PA(16:1(9Z)/5-iso PGF2VI)

C37H65O11P (716.4264)


   

PA(15:0/20:3(8Z,11Z,14Z)-2OH(5,6))

PA(15:0/20:3(8Z,11Z,14Z)-2OH(5,6))

C38H69O10P (716.4628)


   

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/15:0)

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/15:0)

C38H69O10P (716.4628)


   

PA(a-15:0/20:3(8Z,11Z,14Z)-2OH(5,6))

PA(a-15:0/20:3(8Z,11Z,14Z)-2OH(5,6))

C38H69O10P (716.4628)


   

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/a-15:0)

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/a-15:0)

C38H69O10P (716.4628)


   

PA(i-15:0/20:3(8Z,11Z,14Z)-2OH(5,6))

PA(i-15:0/20:3(8Z,11Z,14Z)-2OH(5,6))

C38H69O10P (716.4628)


   

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/i-15:0)

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/i-15:0)

C38H69O10P (716.4628)


   

PA(14:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

PA(14:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

C37H65O11P (716.4264)


   

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/14:0)

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/14:0)

C37H65O11P (716.4264)


   

PA(16:1(9Z)/20:4(6E,8Z,11Z,14Z)+=O(5))

PA(16:1(9Z)/20:4(6E,8Z,11Z,14Z)+=O(5))

C37H65O11P (716.4264)


   

PA(i-14:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

PA(i-14:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

C37H65O11P (716.4264)


   

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/i-14:0)

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/i-14:0)

C37H65O11P (716.4264)


   

Veraguamide E

Veraguamide E

C39H64N4O8 (716.4724)


A natural product found in Symploca hydnoides.

   

methyl (16R,21S)-6-[[(1R,9R,16R,21S)-18-methoxycarbonyl-2-methyl-2,12-diazahexacyclo[14.2.2.19,12.01,9.03,8.016,21]henicosa-3(8),4,6-trien-6-yl]methyl]-2-methyl-2,12-diazahexacyclo[14.2.2.19,12.01,9.03,8.016,21]henicosa-3(8),4,6-triene-18-carboxylate

methyl (16R,21S)-6-[[(1R,9R,16R,21S)-18-methoxycarbonyl-2-methyl-2,12-diazahexacyclo[14.2.2.19,12.01,9.03,8.016,21]henicosa-3(8),4,6-trien-6-yl]methyl]-2-methyl-2,12-diazahexacyclo[14.2.2.19,12.01,9.03,8.016,21]henicosa-3(8),4,6-triene-18-carboxylate

C45H56N4O4 (716.4301)


   

Dgdg O-18:4_3:0

Dgdg O-18:4_3:0

C36H60O14 (716.3983)


   

Dgdg O-16:4_5:0

Dgdg O-16:4_5:0

C36H60O14 (716.3983)


   

PEtOH 16:4_20:4

PEtOH 16:4_20:4

C41H65O8P (716.4417)


   

PEtOH 18:4_18:4

PEtOH 18:4_18:4

C41H65O8P (716.4417)


   

PEtOH 16:3_20:5

PEtOH 16:3_20:5

C41H65O8P (716.4417)


   

PEtOH 18:3_18:5

PEtOH 18:3_18:5

C41H65O8P (716.4417)


   

[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C41H64O10 (716.4499)


   

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-tetradecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-tetradecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C38H69O10P (716.4628)


   

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate

C38H69O10P (716.4628)


   

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate

C38H69O10P (716.4628)


   

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate

C38H69O10P (716.4628)


   

[1-[[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-hydroxypropoxy]-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] hexadecanoate

[1-[[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-hydroxypropoxy]-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] hexadecanoate

C38H69O10P (716.4628)


   

[1-[(2-dodecanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

[1-[(2-dodecanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

C38H69O10P (716.4628)


   

[1-[(2-decanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

[1-[(2-decanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

C38H69O10P (716.4628)


   

[1-[[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-hydroxypropoxy]-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (Z)-hexadec-9-enoate

[1-[[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-hydroxypropoxy]-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (Z)-hexadec-9-enoate

C38H69O10P (716.4628)


   

[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxypropyl] (Z)-hexadec-9-enoate

[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxypropyl] (Z)-hexadec-9-enoate

C38H69O10P (716.4628)


   

[1-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

[1-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C41H65O8P (716.4417)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate

C38H69O10P (716.4628)


   

[2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-phosphonooxypropyl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

[2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-phosphonooxypropyl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

C41H65O8P (716.4417)


   

[1-decanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

[1-decanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

C38H69O10P (716.4628)


   

[1-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxy-3-phosphonooxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

[1-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxy-3-phosphonooxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

C41H65O8P (716.4417)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

C38H69O10P (716.4628)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate

C38H69O10P (716.4628)


   

[1-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

[1-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

C41H65O8P (716.4417)


   

[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxypropyl] hexadecanoate

[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxypropyl] hexadecanoate

C38H69O10P (716.4628)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-tetradecanoyloxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-tetradecanoyloxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C38H69O10P (716.4628)


   

[1-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-phosphonooxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

[1-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-phosphonooxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

C41H65O8P (716.4417)


   

[1-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

[1-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

C41H65O8P (716.4417)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate

C38H69O10P (716.4628)


   

[(2R)-1-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

[(2R)-1-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

C41H65O8P (716.4417)


   

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-tetradecanoyloxypropan-2-yl] (6E,9E,12E)-octadeca-6,9,12-trienoate

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-tetradecanoyloxypropan-2-yl] (6E,9E,12E)-octadeca-6,9,12-trienoate

C38H69O10P (716.4628)


   

2-[[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C40H63NO8P+ (716.4291)


   

[(2R)-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

[(2R)-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

C41H65O8P (716.4417)


   

[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-phosphonooxypropyl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate

[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-phosphonooxypropyl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate

C41H65O8P (716.4417)


   

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (6E,9E)-octadeca-6,9-dienoate

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (6E,9E)-octadeca-6,9-dienoate

C38H69O10P (716.4628)


   

2-[[3-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[3-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C40H63NO8P+ (716.4291)


   

[(2R)-2-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

[(2R)-2-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

C41H65O8P (716.4417)


   

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (9E,11E)-octadeca-9,11-dienoate

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (9E,11E)-octadeca-9,11-dienoate

C38H69O10P (716.4628)


   

[(2R)-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-phosphonooxypropyl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

[(2R)-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-phosphonooxypropyl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

C41H65O8P (716.4417)


   

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (6E,9E)-octadeca-6,9-dienoate

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (6E,9E)-octadeca-6,9-dienoate

C38H69O10P (716.4628)


   

[(2R)-1-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

[(2R)-1-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

C41H65O8P (716.4417)


   

[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-phosphonooxypropyl] (4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoate

[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-phosphonooxypropyl] (4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoate

C41H65O8P (716.4417)


   

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (10E,13E,16E,19E)-docosa-10,13,16,19-tetraenoate

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (10E,13E,16E,19E)-docosa-10,13,16,19-tetraenoate

C41H65O8P (716.4417)


   

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (9E,11E)-octadeca-9,11-dienoate

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (9E,11E)-octadeca-9,11-dienoate

C38H69O10P (716.4628)


   

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (9E,12E)-octadeca-9,12-dienoate

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (9E,12E)-octadeca-9,12-dienoate

C38H69O10P (716.4628)


   

[1-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate

[1-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate

C41H64O10 (716.4499)


   

[(2R)-1-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

[(2R)-1-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

C41H65O8P (716.4417)


   

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-tetradecanoyloxypropyl] (9E,12E,15E)-octadeca-9,12,15-trienoate

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-tetradecanoyloxypropyl] (9E,12E,15E)-octadeca-9,12,15-trienoate

C38H69O10P (716.4628)


   

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

C41H64O10 (716.4499)


   

[3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxypropyl] hexadecanoate

[3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxypropyl] hexadecanoate

C38H69O10P (716.4628)


   

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (2E,4E)-octadeca-2,4-dienoate

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (2E,4E)-octadeca-2,4-dienoate

C38H69O10P (716.4628)


   

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (9E,12E)-octadeca-9,12-dienoate

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (9E,12E)-octadeca-9,12-dienoate

C38H69O10P (716.4628)


   

[(2R)-2-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-phosphonooxypropyl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

[(2R)-2-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-phosphonooxypropyl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

C41H65O8P (716.4417)


   

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-pentadec-9-enoyl]oxypropyl] (9E,12E)-heptadeca-9,12-dienoate

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-pentadec-9-enoyl]oxypropyl] (9E,12E)-heptadeca-9,12-dienoate

C38H69O10P (716.4628)


   

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (5E,8E,11E)-icosa-5,8,11-trienoate

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (5E,8E,11E)-icosa-5,8,11-trienoate

C38H69O10P (716.4628)


   

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-tetradecanoyloxypropyl] (6E,9E,12E)-octadeca-6,9,12-trienoate

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-tetradecanoyloxypropyl] (6E,9E,12E)-octadeca-6,9,12-trienoate

C38H69O10P (716.4628)


   

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (8E,11E,14E)-icosa-8,11,14-trienoate

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (8E,11E,14E)-icosa-8,11,14-trienoate

C38H69O10P (716.4628)


   

[(2R)-2-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

[(2R)-2-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

C41H65O8P (716.4417)


   

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (4E,7E)-hexadeca-4,7-dienoate

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (4E,7E)-hexadeca-4,7-dienoate

C41H64O10 (716.4499)


   

[(2R)-1-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

[(2R)-1-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

C41H65O8P (716.4417)


   

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-tetradecanoyloxypropan-2-yl] (9E,12E,15E)-octadeca-9,12,15-trienoate

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-tetradecanoyloxypropan-2-yl] (9E,12E,15E)-octadeca-9,12,15-trienoate

C38H69O10P (716.4628)


   

[3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(4E,7E)-hexadeca-4,7-dienoyl]oxypropyl] (E)-hexadec-7-enoate

[3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(4E,7E)-hexadeca-4,7-dienoyl]oxypropyl] (E)-hexadec-7-enoate

C38H69O10P (716.4628)


   

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (13E,16E,19E)-docosa-13,16,19-trienoate

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (13E,16E,19E)-docosa-13,16,19-trienoate

C41H65O8P (716.4417)


   

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-dodecanoyloxypropyl] (8E,11E,14E)-icosa-8,11,14-trienoate

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-dodecanoyloxypropyl] (8E,11E,14E)-icosa-8,11,14-trienoate

C38H69O10P (716.4628)


   

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-pentadec-9-enoyl]oxypropan-2-yl] (9E,12E)-heptadeca-9,12-dienoate

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-pentadec-9-enoyl]oxypropan-2-yl] (9E,12E)-heptadeca-9,12-dienoate

C38H69O10P (716.4628)


   

[(2R)-2-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

[(2R)-2-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

C41H65O8P (716.4417)


   

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-dodecanoyloxypropyl] (5E,8E,11E)-icosa-5,8,11-trienoate

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-dodecanoyloxypropyl] (5E,8E,11E)-icosa-5,8,11-trienoate

C38H69O10P (716.4628)


   

[(2R)-1-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

[(2R)-1-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

C41H65O8P (716.4417)


   

[1-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

[1-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

C41H64O10 (716.4499)


   

[(2R)-1-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

[(2R)-1-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoate

C41H65O8P (716.4417)


   

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (2E,4E)-octadeca-2,4-dienoate

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (2E,4E)-octadeca-2,4-dienoate

C38H69O10P (716.4628)


   

phosphatidylglycerol 32:3

phosphatidylglycerol 32:3

C38H69O10P (716.4628)


   
   

MGDG O-32:8;O

MGDG O-32:8;O

C41H64O10 (716.4499)


   
   
   
   
   
   
   

PA P-16:1/22:7;O

PA P-16:1/22:7;O

C41H65O8P (716.4417)


   

PA 14:0/20:4;O3

PA 14:0/20:4;O3

C37H65O11P (716.4264)


   

PA 14:1/20:3;O3

PA 14:1/20:3;O3

C37H65O11P (716.4264)


   

PA 22:0/13:3;O2

PA 22:0/13:3;O2

C38H69O10P (716.4628)


   

PA 22:1/12:3;O3

PA 22:1/12:3;O3

C37H65O11P (716.4264)


   

PA 22:2/12:2;O3

PA 22:2/12:2;O3

C37H65O11P (716.4264)


   
   
   
   
   
   

HBMP 30:4;O

HBMP 30:4;O

C36H61O12P (716.39)


   
   

PG O-30:6;O3

PG O-30:6;O3

C36H61O12P (716.39)


   
   
   

PG P-18:0/13:4;O2

PG P-18:0/13:4;O2

C37H65O11P (716.4264)


   

PG P-18:1/12:4;O3

PG P-18:1/12:4;O3

C36H61O12P (716.39)


   

PG P-18:1/13:3;O2

PG P-18:1/13:3;O2

C37H65O11P (716.4264)


   

PG P-20:0/12:3;O

PG P-20:0/12:3;O

C38H69O10P (716.4628)


   
   

PG 18:2/12:3;O2

PG 18:2/12:3;O2

C36H61O12P (716.39)


   

PG 18:3/12:2;O2

PG 18:3/12:2;O2

C36H61O12P (716.39)


   
   

PG 22:2/8:3;O2

PG 22:2/8:3;O2

C36H61O12P (716.39)


   

PG 22:4/8:1;O2

PG 22:4/8:1;O2

C36H61O12P (716.39)


   
   
   
   
   
   
   
   
   
   
   

16-benzyl-14,18,24-trihydroxy-3-(2-hydroxypropan-2-yl)-4,20-dimethyl-13-(sec-butyl)-1,4,10,11,14,17,20,26-octaazatricyclo[20.4.0.0⁶,¹¹]hexacos-17-ene-2,5,12,15,21-pentone

16-benzyl-14,18,24-trihydroxy-3-(2-hydroxypropan-2-yl)-4,20-dimethyl-13-(sec-butyl)-1,4,10,11,14,17,20,26-octaazatricyclo[20.4.0.0⁶,¹¹]hexacos-17-ene-2,5,12,15,21-pentone

C34H52N8O9 (716.3857)


   

(1s,2r,3r,6e,8s,9s,10s,12r,16s)-9-{[(2s,3r,4s,6r)-3,4-dihydroxy-4-[(1s)-1-hydroxyethyl]-6-methyloxan-2-yl]oxy}-2-({[(2r,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy}methyl)-3,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadec-6-ene-5,13-dione

(1s,2r,3r,6e,8s,9s,10s,12r,16s)-9-{[(2s,3r,4s,6r)-3,4-dihydroxy-4-[(1s)-1-hydroxyethyl]-6-methyloxan-2-yl]oxy}-2-({[(2r,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy}methyl)-3,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadec-6-ene-5,13-dione

C36H60O14 (716.3983)


   

[(3s,4s,4ar,6ar,6bs,8r,8ar,9r,10r,12as,14ar,14br)-3,9,10-tris(acetyloxy)-8a-[(acetyloxy)methyl]-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-4-yl]methyl acetate

[(3s,4s,4ar,6ar,6bs,8r,8ar,9r,10r,12as,14ar,14br)-3,9,10-tris(acetyloxy)-8a-[(acetyloxy)methyl]-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-4-yl]methyl acetate

C40H60O11 (716.4135)


   

(3s,6r,7s,10s,13r,16s,21as)-3,13-bis[(2r)-butan-2-yl]-16-[(2s)-butan-2-yl]-8-hydroxy-10-isopropyl-2,7,12-trimethyl-6-(pent-4-yn-1-yl)-3h,6h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-f]1,10-dioxa-4,7,13,16-tetraazacyclononadecane-1,4,11,14,17-pentone

(3s,6r,7s,10s,13r,16s,21as)-3,13-bis[(2r)-butan-2-yl]-16-[(2s)-butan-2-yl]-8-hydroxy-10-isopropyl-2,7,12-trimethyl-6-(pent-4-yn-1-yl)-3h,6h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-f]1,10-dioxa-4,7,13,16-tetraazacyclononadecane-1,4,11,14,17-pentone

C39H64N4O8 (716.4724)


   

(1s)-1-(acetyloxy)-1-[(2r,4s,5s)-5-(acetyloxy)-4-[(1s,2r,3r,5r,7r,10s,11r,14r,15s)-3,7-bis(acetyloxy)-2,6,6,10-tetramethylpentacyclo[12.3.1.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]octadecan-15-yl]oxolan-2-yl]-2-methylpropan-2-yl acetate

(1s)-1-(acetyloxy)-1-[(2r,4s,5s)-5-(acetyloxy)-4-[(1s,2r,3r,5r,7r,10s,11r,14r,15s)-3,7-bis(acetyloxy)-2,6,6,10-tetramethylpentacyclo[12.3.1.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]octadecan-15-yl]oxolan-2-yl]-2-methylpropan-2-yl acetate

C40H60O11 (716.4135)


   

(1r,3r,3as,3bs,5s,5as,7s,9as,9br,11ar)-1-[(2r,5s)-5-{[(2r,3r,4r,5s)-3,4-dihydroxy-5-({[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}methyl)oxolan-2-yl]oxy}-6-methylheptan-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-3,3b,5,7-tetrol

(1r,3r,3as,3bs,5s,5as,7s,9as,9br,11ar)-1-[(2r,5s)-5-{[(2r,3r,4r,5s)-3,4-dihydroxy-5-({[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}methyl)oxolan-2-yl]oxy}-6-methylheptan-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-3,3b,5,7-tetrol

C37H64O13 (716.4347)


   

(2s,3r,4s,5r)-2-{[(1r,3r,3as,3bs,5s,5as,7s,9as,9br,11ar)-3,3b,5-trihydroxy-9a,11a-dimethyl-1-[(2r,5s)-6-methyl-5-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}heptan-2-yl]-tetradecahydrocyclopenta[a]phenanthren-7-yl]oxy}oxane-3,4,5-triol

(2s,3r,4s,5r)-2-{[(1r,3r,3as,3bs,5s,5as,7s,9as,9br,11ar)-3,3b,5-trihydroxy-9a,11a-dimethyl-1-[(2r,5s)-6-methyl-5-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}heptan-2-yl]-tetradecahydrocyclopenta[a]phenanthren-7-yl]oxy}oxane-3,4,5-triol

C37H64O13 (716.4347)


   

(3e,5s,6s,7s,9s,13e,15r,16r)-6-{[(2s,3r,4s,6r)-3,4-dihydroxy-4-[(1s)-1-hydroxyethyl]-6-methyloxan-2-yl]oxy}-9-hydroxy-15-({[(2r,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy}methyl)-5,7,9,16-tetramethyl-1-oxacyclohexadeca-3,13-diene-2,10-dione

(3e,5s,6s,7s,9s,13e,15r,16r)-6-{[(2s,3r,4s,6r)-3,4-dihydroxy-4-[(1s)-1-hydroxyethyl]-6-methyloxan-2-yl]oxy}-9-hydroxy-15-({[(2r,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxy}methyl)-5,7,9,16-tetramethyl-1-oxacyclohexadeca-3,13-diene-2,10-dione

C36H60O14 (716.3983)


   

(2s,3r,4s,5r)-2-{[(1r,3s,3as,3bs,5r,5as,7s,9as,9br,11ar)-3,3b,5-trihydroxy-9a,11a-dimethyl-1-[(2r,5s)-6-methyl-5-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}heptan-2-yl]-tetradecahydrocyclopenta[a]phenanthren-7-yl]oxy}oxane-3,4,5-triol

(2s,3r,4s,5r)-2-{[(1r,3s,3as,3bs,5r,5as,7s,9as,9br,11ar)-3,3b,5-trihydroxy-9a,11a-dimethyl-1-[(2r,5s)-6-methyl-5-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}heptan-2-yl]-tetradecahydrocyclopenta[a]phenanthren-7-yl]oxy}oxane-3,4,5-triol

C37H64O13 (716.4347)


   

1-{5-[(3,4-dihydroxy-5-{[(3,4,5-trihydroxyoxan-2-yl)oxy]methyl}oxolan-2-yl)oxy]-6-methylheptan-2-yl}-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-3,3b,5,7-tetrol

1-{5-[(3,4-dihydroxy-5-{[(3,4,5-trihydroxyoxan-2-yl)oxy]methyl}oxolan-2-yl)oxy]-6-methylheptan-2-yl}-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-3,3b,5,7-tetrol

C37H64O13 (716.4347)


   

n-{2-[hydroxy({[1-(8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl)-3-methylbutyl]-c-hydroxycarbonimidoyl})methyl]-5-oxooxolan-3-yl}-2-[(1-hydroxy-10-methyldodecylidene)amino]butanediimidic acid

n-{2-[hydroxy({[1-(8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl)-3-methylbutyl]-c-hydroxycarbonimidoyl})methyl]-5-oxooxolan-3-yl}-2-[(1-hydroxy-10-methyldodecylidene)amino]butanediimidic acid

C37H56N4O10 (716.3996)


   

[3,9,10-tris(acetyloxy)-8a-[(acetyloxy)methyl]-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-4-yl]methyl acetate

[3,9,10-tris(acetyloxy)-8a-[(acetyloxy)methyl]-8-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-4-yl]methyl acetate

C40H60O11 (716.4135)


   

(2s)-n-[(2s,3s)-2-[(s)-hydroxy({[(1s)-1-[(3s)-8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl]-3-methylbutyl]-c-hydroxycarbonimidoyl})methyl]-5-oxooxolan-3-yl]-2-[(1-hydroxy-10-methyldodecylidene)amino]butanediimidic acid

(2s)-n-[(2s,3s)-2-[(s)-hydroxy({[(1s)-1-[(3s)-8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl]-3-methylbutyl]-c-hydroxycarbonimidoyl})methyl]-5-oxooxolan-3-yl]-2-[(1-hydroxy-10-methyldodecylidene)amino]butanediimidic acid

C37H56N4O10 (716.3996)


   

1-[(1r,3as,5ar,5br,7ar,9s,11ar,11br,13ar,13br)-9-{[(2e)-3-(4-hydroxyphenyl)prop-2-enoyl]oxy}-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-hexadecahydrocyclopenta[a]chrysen-3a-yl]methyl 4-ethyl butanedioate

1-[(1r,3as,5ar,5br,7ar,9s,11ar,11br,13ar,13br)-9-{[(2e)-3-(4-hydroxyphenyl)prop-2-enoyl]oxy}-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-hexadecahydrocyclopenta[a]chrysen-3a-yl]methyl 4-ethyl butanedioate

C45H64O7 (716.4652)


   

(3s,6r,7s,10s,13s,16s,21as)-10,13,16-tris[(2s)-butan-2-yl]-8-hydroxy-3-isopropyl-2,7,12-trimethyl-6-(pent-4-yn-1-yl)-3h,6h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-f]1,10-dioxa-4,7,13,16-tetraazacyclononadecane-1,4,11,14,17-pentone

(3s,6r,7s,10s,13s,16s,21as)-10,13,16-tris[(2s)-butan-2-yl]-8-hydroxy-3-isopropyl-2,7,12-trimethyl-6-(pent-4-yn-1-yl)-3h,6h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-f]1,10-dioxa-4,7,13,16-tetraazacyclononadecane-1,4,11,14,17-pentone

C39H64N4O8 (716.4724)


   

1-(acetyloxy)-1-[5-(acetyloxy)-4-[3,7-bis(acetyloxy)-2,6,6,10-tetramethylpentacyclo[12.3.1.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]octadecan-15-yl]oxolan-2-yl]-2-methylpropan-2-yl acetate

1-(acetyloxy)-1-[5-(acetyloxy)-4-[3,7-bis(acetyloxy)-2,6,6,10-tetramethylpentacyclo[12.3.1.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]octadecan-15-yl]oxolan-2-yl]-2-methylpropan-2-yl acetate

C40H60O11 (716.4135)


   

n-{2-[hydroxy({[1-(8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl)-3-methylbutyl]-c-hydroxycarbonimidoyl})methyl]-5-oxooxolan-3-yl}-2-[(1-hydroxy-10-methylundecylidene)amino]pentanediimidic acid

n-{2-[hydroxy({[1-(8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl)-3-methylbutyl]-c-hydroxycarbonimidoyl})methyl]-5-oxooxolan-3-yl}-2-[(1-hydroxy-10-methylundecylidene)amino]pentanediimidic acid

C37H56N4O10 (716.3996)


   

(3s,6r,7s,10s,13s,16s,21as)-3-[(2r)-butan-2-yl]-13,16-bis[(2s)-butan-2-yl]-8-hydroxy-10-isopropyl-2,7,12-trimethyl-6-(pent-4-yn-1-yl)-3h,6h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-f]1,10-dioxa-4,7,13,16-tetraazacyclononadecane-1,4,11,14,17-pentone

(3s,6r,7s,10s,13s,16s,21as)-3-[(2r)-butan-2-yl]-13,16-bis[(2s)-butan-2-yl]-8-hydroxy-10-isopropyl-2,7,12-trimethyl-6-(pent-4-yn-1-yl)-3h,6h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-f]1,10-dioxa-4,7,13,16-tetraazacyclononadecane-1,4,11,14,17-pentone

C39H64N4O8 (716.4724)


   

8-hydroxy-3-isopropyl-2,7,12-trimethyl-6-(pent-4-yn-1-yl)-10,13,16-tris(sec-butyl)-3h,6h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-f]1,10-dioxa-4,7,13,16-tetraazacyclononadecane-1,4,11,14,17-pentone

8-hydroxy-3-isopropyl-2,7,12-trimethyl-6-(pent-4-yn-1-yl)-10,13,16-tris(sec-butyl)-3h,6h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-f]1,10-dioxa-4,7,13,16-tetraazacyclononadecane-1,4,11,14,17-pentone

C39H64N4O8 (716.4724)


   

3,15-dibenzyl-1,4,7,10,13-pentahydroxy-9-isopropyl-6,12-bis(2-methylpropyl)-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-a]1,4,7,10,13,16-hexaazacyclooctadecan-16-one

3,15-dibenzyl-1,4,7,10,13-pentahydroxy-9-isopropyl-6,12-bis(2-methylpropyl)-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-a]1,4,7,10,13,16-hexaazacyclooctadecan-16-one

C40H56N6O6 (716.4261)


   

1-ethyl 4-(9-{[3-(4-hydroxyphenyl)prop-2-enoyl]oxy}-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-hexadecahydrocyclopenta[a]chrysen-3a-yl)methyl butanedioate

1-ethyl 4-(9-{[3-(4-hydroxyphenyl)prop-2-enoyl]oxy}-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-hexadecahydrocyclopenta[a]chrysen-3a-yl)methyl butanedioate

C45H64O7 (716.4652)


   

(1r,3r,3as,3bs,5s,5as,7s,9as,9br,11ar)-1-[(2r,5s)-5-{[(2r,3r,4s,5s)-3,4-dihydroxy-5-({[(2r,3s,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}methyl)oxolan-2-yl]oxy}-6-methylheptan-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-3,3b,5,7-tetrol

(1r,3r,3as,3bs,5s,5as,7s,9as,9br,11ar)-1-[(2r,5s)-5-{[(2r,3r,4s,5s)-3,4-dihydroxy-5-({[(2r,3s,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}methyl)oxolan-2-yl]oxy}-6-methylheptan-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-3,3b,5,7-tetrol

C37H64O13 (716.4347)


   

(1r,3s,3ar,5ar,7r,9as,11ar)-3-hydroxy-1-[(2r)-1-[(3-methoxy-3-oxopropanoyl)oxy]-6-methylhept-5-en-2-yl]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl 1-methyl (3s)-3-hydroxy-3-methylpentanedioate

(1r,3s,3ar,5ar,7r,9as,11ar)-3-hydroxy-1-[(2r)-1-[(3-methoxy-3-oxopropanoyl)oxy]-6-methylhept-5-en-2-yl]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl 1-methyl (3s)-3-hydroxy-3-methylpentanedioate

C41H64O10 (716.4499)


   

(2s)-n-[(2s,3s)-2-[(s)-hydroxy({[(1s)-1-[(3s)-8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl]-3-methylbutyl]-c-hydroxycarbonimidoyl})methyl]-5-oxooxolan-3-yl]-2-[(1-hydroxy-10-methylundecylidene)amino]pentanediimidic acid

(2s)-n-[(2s,3s)-2-[(s)-hydroxy({[(1s)-1-[(3s)-8-hydroxy-1-oxo-3,4-dihydro-2-benzopyran-3-yl]-3-methylbutyl]-c-hydroxycarbonimidoyl})methyl]-5-oxooxolan-3-yl]-2-[(1-hydroxy-10-methylundecylidene)amino]pentanediimidic acid

C37H56N4O10 (716.3996)


   

2-[(3,3b,5-trihydroxy-9a,11a-dimethyl-1-{6-methyl-5-[(3,4,5-trihydroxyoxan-2-yl)oxy]heptan-2-yl}-tetradecahydrocyclopenta[a]phenanthren-7-yl)oxy]oxane-3,4,5-triol

2-[(3,3b,5-trihydroxy-9a,11a-dimethyl-1-{6-methyl-5-[(3,4,5-trihydroxyoxan-2-yl)oxy]heptan-2-yl}-tetradecahydrocyclopenta[a]phenanthren-7-yl)oxy]oxane-3,4,5-triol

C37H64O13 (716.4347)


   

1-[(1r,3as,5ar,5br,7ar,9s,11as,11br,13ar,13bs)-9-{[(2e)-3-(4-hydroxyphenyl)prop-2-enoyl]oxy}-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-hexadecahydrocyclopenta[a]chrysen-3a-yl]methyl 4-ethyl butanedioate

1-[(1r,3as,5ar,5br,7ar,9s,11as,11br,13ar,13bs)-9-{[(2e)-3-(4-hydroxyphenyl)prop-2-enoyl]oxy}-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-hexadecahydrocyclopenta[a]chrysen-3a-yl]methyl 4-ethyl butanedioate

C45H64O7 (716.4652)


   

(2r,3s,8s,13r,14s,19s)-8,19-dibutyl-3,14-dimethyl-13-{[(2s,3r,4r,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}tricyclo[18.2.2.2⁹,¹²]hexacosa-1(22),9,11,20,23,25-hexaene-2,10,21,24,26-pentol

(2r,3s,8s,13r,14s,19s)-8,19-dibutyl-3,14-dimethyl-13-{[(2s,3r,4r,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}tricyclo[18.2.2.2⁹,¹²]hexacosa-1(22),9,11,20,23,25-hexaene-2,10,21,24,26-pentol

C41H64O10 (716.4499)


   

8-hydroxy-10-isopropyl-2,7,12-trimethyl-6-(pent-4-yn-1-yl)-3,13,16-tris(sec-butyl)-3h,6h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-f]1,10-dioxa-4,7,13,16-tetraazacyclononadecane-1,4,11,14,17-pentone

8-hydroxy-10-isopropyl-2,7,12-trimethyl-6-(pent-4-yn-1-yl)-3,13,16-tris(sec-butyl)-3h,6h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-f]1,10-dioxa-4,7,13,16-tetraazacyclononadecane-1,4,11,14,17-pentone

C39H64N4O8 (716.4724)


   

(3s,6r,9s,12s,15r,20as)-3,15-dibenzyl-1,4,7,10,13-pentahydroxy-9-isopropyl-6,12-bis(2-methylpropyl)-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-a]1,4,7,10,13,16-hexaazacyclooctadecan-16-one

(3s,6r,9s,12s,15r,20as)-3,15-dibenzyl-1,4,7,10,13-pentahydroxy-9-isopropyl-6,12-bis(2-methylpropyl)-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-a]1,4,7,10,13,16-hexaazacyclooctadecan-16-one

C40H56N6O6 (716.4261)


   

3-[(3s,3as,5r,5ar,6r,7r,9r,9ar)-5-{[(2r)-2-hydroxy-3-methylbutanoyl]oxy}-9-{[(2r,3e)-2-hydroxy-3-methylpent-3-enoyl]oxy}-7-(2-hydroxypropan-2-yl)-3a,6,9a-trimethyl-3-[(3s,5s)-5-(2-methylprop-1-en-1-yl)oxolan-3-yl]-2h,3h,4h,5h,5ah,7h,8h,9h-cyclopenta[a]naphthalen-6-yl]propanoic acid

3-[(3s,3as,5r,5ar,6r,7r,9r,9ar)-5-{[(2r)-2-hydroxy-3-methylbutanoyl]oxy}-9-{[(2r,3e)-2-hydroxy-3-methylpent-3-enoyl]oxy}-7-(2-hydroxypropan-2-yl)-3a,6,9a-trimethyl-3-[(3s,5s)-5-(2-methylprop-1-en-1-yl)oxolan-3-yl]-2h,3h,4h,5h,5ah,7h,8h,9h-cyclopenta[a]naphthalen-6-yl]propanoic acid

C41H64O10 (716.4499)